In fine, our results not only show that the activities of human MOs change when they interact with autologous primary breast cancer cells, but also provide the first evidence that MET treatment can have a potent role in reversing the effects of the crosstalk between MOs and breast cancer cells, especially on the production of co-operative ‘antitumor IFN-γ’ and ‘regulatory IL-10’ cytokines, intracellular calcium signals, as well as immune-metabolic and protective redox based-biomarkers as summarized in the graphical abstract (S2 Fig). The gene discussed is IFNG; the disease is breast carcinoma.